Kronos Bio Inc (KRON) - News Archive

In a compelling presentation at the ACR Convergence 2024, Kronos Bio shared significant preclinical data demonstrating the effectiveness of p300 KAT (lysine acetyltransferase) inhibitors in reducing inflammation. This r...

In the ever-evolving landscape of oncology, the role of specific targets in overcoming cancer s complex mechanisms is paramount. Recently, Kronos Bio made significant strides in this arena, presenting compelling data at...

Kronos Bio Inc. has announced a significant milestone in its development pipeline, unveiling KB-7898 as its inaugural candidate for autoimmune diseases, specifically targeting Sjögren’s disease. This candidate is a p300...

At the recent American Association for Cancer Research (AACR) Ovarian Cancer Research Symposium, Kronos Bio Inc. presented promising data that may pave the way for the clinical evaluation of its investigational therapy,...

Kronos Bio, a prominent cancer-focused biotechnology company, has announced significant advancements in their ongoing clinical trial of KB-0742, an oral CDK9 inhibitor. The Phase 1/2 trial, KB-0742-1001, aims to evaluat...

Kronos Bio Advances Promising Cancer Therapeutic KB-0742 with Positive Clinical Trial UpdateSan Mateo, Calif. and Cambridge, Mass., March 05, 2024 - Kronos Bio, Inc. (Nasdaq: KRON), a leader in developing innovative can...

Kronos Bio, Inc., a leading biopharmaceutical company focused on revolutionizing cancer therapies, is set to present exciting updates on its Phase 1/2 clinical trial of KB-0742, an innovative oral CDK9 inhibitor. The pr...

In recent news, Kronos Bio, a clinical-stage biopharmaceutical company, has announced a strategic restructuring aimed at optimizing resources for its clinical development efforts. The company plans to focus primarily on...

Kronos Bio s Presentation at AACR 2024 Annual Meeting Highlights Cutting-Edge Advances in Cancer Research San Mateo, California and Cambridge, Massachusetts - Kronos Bio, Inc. (Nasdaq: KRON), a pioneering company commit...

In a move to propel its pipeline advancement and streamline operations, Kronos Bio Inc has recently implemented a new leadership structure. This restructuring includes the elimination of three executive officer roles an...

In a recent pipeline update, Kronos Bio, a leading clinical-stage biopharmaceutical company, has made significant strides in their research and development efforts. While showcasing progress in their Phase 1b study for...

Kronos Bio, a leading biopharmaceutical company, recently presented positive preliminary data from the ongoing Phase 1/2 KB-0742 study at the Connective Tissue Oncology Society Annual Meeting. The study s findings were...